LTFS
OVID icon

Ladenburg Thalmann Financial Services’s Ovid Therapeutics OVID Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
200
– – ﹤0.01% 5215
2019
Q3 		$1K Buy
+200
New +$455 ﹤0.01% 5140

Other funds holding OVID

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ladenburg Thalmann Financial Services's OVID Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Ovid Therapeutics (OVID) position steady in Q4 2019 at 200 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5215.

Ladenburg Thalmann Financial Services first reported a position in OVID in Q3 2019 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold OVID as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 200 shares of Ovid Therapeutics worth $1K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Ovid Therapeutics share count unchanged in Q4 2019.
  • Ovid Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5215 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.